Hepion Pharmaceuticals, Inc. (HEPA) Return on equity 2020–2023
Hepion Pharmaceuticals, Inc. (HEPA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-672.0%FY2023 · since FY2020: -50.2% → -672.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -672.0% | -587.3 pp |
| FY2022 | -84.6% | -49.5 pp |
| FY2021 | -35.2% | +15.0 pp |
| FY2020 | -50.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More HEPA financial trends
HEPA RevenueHEPA Net incomeHEPA Net marginHEPA Gross profitHEPA Gross marginHEPA Operating incomeHEPA Operating marginHEPA Operating cash flowHEPA Free cash flowHEPA Capital expendituresHEPA Stock buybacksHEPA Dividends paidHEPA Total assetsHEPA Total liabilitiesHEPA Shareholders’ equityHEPA overview →